Herbalife reported fourth quarter and full-year 2025 results with net sales growth exceeding guidance, driven by strong performance in Latin America and EMEA, and maintained adjusted EBITDA margins. The company also announced a strategic investment from Cristiano Ronaldo in its Pro2col technology, signaling a focus on innovation and personalized wellness platforms.
Fourth quarter net sales increased 6.3% year-over-year to $1.3 billion, exceeding guidance.
positiveFull-year 2025 net sales increased 0.9% to $5.0 billion, exceeding guidance.
positiveAdjusted EBITDA margin for the full year 2025 was 13.1%, an expansion of 40 basis points compared to 2024.
positiveNet cash provided by operating activities was $333.3 million for the full year 2025.
positiveFourth quarter gross profit margin decreased by 30 basis points year-over-year to 77.5%, primarily due to unfavorable sales mix and input cost inflation.
attentionFourth quarter adjusted EBITDA margin decreased by 20 basis points year-over-year to 12.2%, impacted by approximately $12 million of FX headwinds.
attentionFull-year 2025 net sales growth of 0.9% was impacted by 160 basis points of foreign currency headwinds.
attentionChina region net sales declined 4.4% in Q4 2025 and 6.2% for FY 2025.
attentionInventories increased to $511.7 million as of December 31, 2025, from $475.4 million as of December 31, 2024.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
North America | N/A | — | — | — | -0.8% |
Latin America | N/A | — | — | — | +10.5% |
EMEA | N/A | — | — | — | +2.3% |
Asia Pacific | N/A | — | — | — | +3.0% |
China | N/A | — | — | — | -6.3% |
| Total Revenue | $0.00M | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Our results reflect strong operational and financial momentum.
For the full year, we delivered our second consecutive year of adjusted EBITDA and adjusted EBITDA margin expansion, generated strong operating cash flows, reduced debt, and ended 2025 with a total leverage ratio of 2.8x.
Today, we are building on that legacy—combining science, data, AI, innovation, and community to bring the next generation of personalized nutrition and wellness to more people around the world.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.